about
Calcitonin for metastatic bone painPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerNational consensus in China on diagnosis and treatment of patients with advanced breast cancerWhere Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trialsMain controversies in breast cancerMolecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone-Targeted TherapyChemotherapy- and irradiation-induced bone loss in adults with solid tumorsBone-targeted therapy in metastatic breast cancer - all well-established knowledge?The best of both worlds - managing the cancer, saving the bone.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer.Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trialsTreatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeBone-Targeted Agents for the Management of Breast Cancer Patients with Bone MetastasesCost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.Clinical nomogram to predict bone-only metastasis in patients with early breast carcinomaBisphosphonates in the Treatment of Patients With Metastatic Breast, Lung, and Prostate Cancer: A Meta-Analysis.Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre.Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapyRisk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China.Impact of denosumab on bone mass in cancer patients.Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial.Prognostic factors and survival in metastatic breast cancer: A single institution experience.Design and Biological Evaluation of Delivery Systems Containing BisphosphonatesMonocyte subpopulations in angiogenesis.Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study.The Metastatic Spine Disease Multidisciplinary Working Group Algorithms.Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.Kasabach-Merritt syndrome combined with hypercalcemia: A case report.Bisphosphonates for advanced prostate cancer.Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain.Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).Bisphosphonates and other bone agents for breast cancer.
P2860
Q24245128-F0B7CC8F-68AD-4DED-AC81-D82F0F47CAF4Q26746212-403F349F-EEB2-4C44-82B6-1A8E344F786EQ26775621-67A7E25D-39F6-4075-A5C0-213C3A86116FQ26849473-B5BB113E-B44B-4DD9-8E16-86485743856EQ26861586-C33E9CF4-A0A4-47C4-B1E5-FAD92A731D60Q27026673-46D3E3B0-FEB2-4726-BFB9-1C879A556493Q28068956-2E7198E2-2DF4-4F0D-9352-114C780CFF84Q28076646-71DC6F96-F123-4225-B7A8-84280E626C76Q28081294-283BDCAD-D739-4D24-BC26-D02D43B62C3AQ28084019-DD9374DF-0123-4869-BA97-FC42776B6623Q28087676-9BD224FE-1687-41AB-BDEC-F18F862198AAQ33920055-B1A42AA3-9E32-4BF8-BBA2-FDEB5862FB6FQ34042715-CEDAD853-F2C0-40D2-A4EE-54FDD43D0EBBQ35208717-17E08D83-607A-4C8B-A82A-143DCE4E18A2Q35650666-C44FD43E-63B7-4C11-B2EC-A0AA1466623EQ35667196-D3BC815E-3C60-4C2E-822F-08ECFAB70EBAQ35750641-3A0F5ACF-61B7-4E05-94B9-CFA332BB0646Q35934290-BDED0E7A-4463-4768-A37E-6513319D5A2FQ36295018-99EC687B-CFBF-4FD6-B378-79552784E4D4Q36299278-DBBCCA9C-DDE3-42DE-B00D-507E3E388F3FQ36491533-65247F81-1A67-4D69-8B44-E1AF12E99730Q36491642-15CB9318-A3D4-49D4-BB58-F0CD50ACAE9FQ36492209-3EA6046A-00A7-4519-AF77-35B3A2BB946BQ36788277-9F6913DB-CAAA-446D-9C75-6F150F738695Q36836736-1D24190F-172E-4415-BD2B-C448EC52B595Q37000157-2B6058BF-B674-41C3-9AC2-E4E1DE2DC567Q37094993-50167E54-7AB7-4FDB-ACFC-39E81F6C8244Q37392167-3C710740-2382-4A49-8E61-C8330D2B9010Q37731222-F1819DD9-FC24-474F-B640-4B633D8C62F3Q38189962-4C4C0319-482B-42A6-AB49-655C709E84D5Q38911203-7658F580-1F05-4CCD-9548-FEBAEE755424Q40554954-E5980227-7A15-4DF2-AC5D-60A7D110F5A3Q41450381-92A2CFAD-54EF-43D8-B629-930C5D0BB410Q42363605-E5213936-B30D-4654-9433-0C70A0180817Q42784340-E2B9E40A-D0F8-416D-A1BA-ABB08CFF03CAQ47134310-F9FC9FA1-1C54-4493-8CDF-DD645DFDA8D3Q47248454-05D4751C-92D9-46B1-BBE7-374E1BE4BC75Q47557846-81E517A4-130F-41C5-A4FC-A5321BFC217CQ47663622-D915976E-3D6D-4D3B-8C6B-A4D94B1C6CEEQ47693752-9C9F1BBE-75AE-4A5B-967D-AD9E8E206FC9
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Bisphosphonates and other bone agents for breast cancer
@ast
Bisphosphonates and other bone agents for breast cancer
@en
Bisphosphonates and other bone agents for breast cancer
@en-gb
Bisphosphonates and other bone agents for breast cancer
@nl
type
label
Bisphosphonates and other bone agents for breast cancer
@ast
Bisphosphonates and other bone agents for breast cancer
@en
Bisphosphonates and other bone agents for breast cancer
@en-gb
Bisphosphonates and other bone agents for breast cancer
@nl
prefLabel
Bisphosphonates and other bone agents for breast cancer
@ast
Bisphosphonates and other bone agents for breast cancer
@en
Bisphosphonates and other bone agents for breast cancer
@en-gb
Bisphosphonates and other bone agents for breast cancer
@nl
P2093
P2860
P3181
P1476
Bisphosphonates and other bone agents for breast cancer
@en
P2093
Martin R Stockler
Matthew HF Wong
Nick Pavlakis
P2860
P3181
P356
10.1002/14651858.CD003474.PUB3
P577
2012-02-15T00:00:00Z